TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-myeloid malignancy and receiving chemotherapy~* Baseline Hb of \<= 11 g/dL~* Planned chemotherapy for a minimum of 15 weeks to be administered every 3 weeks~* Female patients with reproductive potential must have a negative serum pregnancy test at screening.~Exclusion Criteria:~* No uncontrolled hypertension or recent history (within 6 months) of uncontrolled cardiac arrhythmias~* No pulmonary embolism~* or thrombosis~* No transfusion of white blood cells or packed red blood cells within 28 days of Epoetin alfa treatment~* No prior treatment with Epoetin alfa or any other erythropoetic agent within the previous three months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female ≥18 to ≤45 years old at the time of enrollment~* Regular monthly menstrual cycle during the last 12 months~* Good general health based on a medical history evaluation and physical examination~* No clinically significant abnormalities in laboratory tests at screening~* Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures~Exclusion Criteria:~* Intolerance to any recent oral contraceptive in the last three (3) years,~* Female subjects with a positive serum pregnancy test at screening~* Female subjects not willing to inform her sexual partner of her participation in the clinical study~* Use of any over the counter or prescription medications within the 14 days or 5 half lives (whichever is longer)~* Nicotine use eg cigarettes or equivalent during 12 months prior to day 1 and through the duration of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Erenumab + Estrogen/Progestin Contraceptive (Type: EXPERIMENTAL): Participants received a combination oral contraceptive for 3 28-day cycles during the study.~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patient receiving insulin for the treatment of documented diagnosis of Type 1 Diabetes Mellitus (T1DM) for at least 1 year at the time of Visit 1~* Fasting C-peptide value of \< 0.7 ng/mL (0.23 nmol/L) at Visit 2 measured by the central laboratory~* Use of, and be willing, based on the Investigator's judgement, to continue throughout the duration of the trial, either:~  * Multiple Daily Injections (MDI) of insulin consisting of at least one basal insulin injection and at least three daily bolus injections OR~ * Continuous Subcutaneous Insulin Infusion (CSII) of any insulin type, with at least 5 months experience of using CSII prior to Visit 1~* HbA1c \>/= 7.5% and \</= 10.0% at Visit 5 measured by the central laboratory~* Age \>/= 18 years at Visit 1~Additional inclusion criteria may apply~Exclusion criteria:~* History of Type 2 Diabetes Mellitus (T2DM), maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis~* Pancreas, pancreatic islet cells or renal transplant recipient~* T1DM treatment with any other antihyperglycaemic drug (e.g. metformin, alpha-glucosidase inhibitors, Glucagon-like-peptide 1 (GLP-1) analogues, Sodium-Glucose Co-Transporter (SGLT-2) inhibitors, pramlintide, inhaled insulin, pre-mixed insulins etc.) except subcutaneous basal and bolus insulin within 3 months prior to Visit 1~* Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that required hospitalisation or hypoglycaemia-related treatment by an emergency physician or paramedic within 3 months prior to Visit 1 and until randomisation~* Occurence of Diabetic Ketoacidosis (DKA) within 3 months prior to Visit 1 and until randomisation~Additional exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low dose (Type: EXPERIMENTAL): Empagliflozin tablets once daily
- Empagliflozin high dose (Type: EXPERIMENTAL): Empagliflozin tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching empagliflozin once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patient (≥18 years old) with MS.~* Patient receiving Fampyra® for walking disability (EDSS 4-7).~* Patient receiving stable doses of any Disease Modifying Treatment (DMT) for at least 3 months prior to study entry.~* Patients will receive Fampyra® in line with the approved Summary of Product Characteristics (SmPC).~* Patients for whom the decision to prescribe therapy with Fampyra according to the locally approved product's summary of product characteristics (SmPC) has already been taken prior to their enrollment in the study and is clearly separated from the physician's decision to include the patient in the current study.~* Patients must have signed an informed consent document.~* Patients must be able to read, understand and complete the study specific questionnaires.~Exclusion Criteria:~* Pregnant or lactating woman.~* Patient with prior history or current presentation of seizure.~* Patient with mild, moderate or severe renal impairment (creatinine clearance \< 80 ml/min).~* Concurrent treatment with other medicinal products containing fampridine (4-aminopyridine).~* Concomitant treatment with medicinal products that are inhibitors of Organic Transporter 2 (OCT2), e.g., cimetidine.~* Patients who have received more than 1 dose of fampridine at the time of enrollment into the study.~* Patients that meet any of the contraindications to the administration of the study drug according to the approved SmPC.~* Patients who currently receive treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) before the commencement of therapy with fampridine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older~* Best-corrected visual acuity (BCVA) of 20/40 or better (Snellen equivalent), using the logarithm of the minimum angle of resolution (LogMAR) in each eye~* Evidence of meibomian gland obstruction~* Reported dry eye signs and symptoms within the past 3 months~Exclusion Criteria:~* Uncontrolled ocular disease (except for MGD and dry eye disease/keratoconjunctivitis sicca) or uncontrolled systemic disease~* Glaucoma, ocular hypertension, or intraocular pressure (IOP) in either eye at screening ≥24 mm Hg or has planned insertion/removal of glaucoma filtration shunts/devices during the study~* Corneal abnormality or disorder that impacts normal spreading of the tear film or corneal integrity~* BCVA worse than 20/40 in either eye~* Current use of punctal plugs, anticipated insertion during the study, or a history of punctal cautery in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZR-MD-001 Low Dose (Type: EXPERIMENTAL): AZR-MD-001 Low Dose will be dosed up to once daily.
- AZR-MD-001 Mid Dose (Type: EXPERIMENTAL): AZR-MD-001 Mid Dose will be dosed up to once daily.
- AZR-MD-001 High Dose (Type: EXPERIMENTAL): AZR-MD-001 High Dose will be dosed up to once daily.
- AZR-MD-001 Vehicle (Type: SHAM_COMPARATOR): AZR-MD-001 Vehicle will be dosed up to once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Allopurinol on Insulin Resistance and Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, age 40 -65 yrs~Exclusion Criteria:~* None

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): Placebo
- 2 (Type: ACTIVE_COMPARATOR): Allopurinol given for 2 weeks with diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Anatomopathological samples (surgical specimens or when a surgical sample is not possible, a core needle biopsy may be used) from female participants with a histopathological diagnosis of invasive breast cancer~Exclusion Criteria:~* Samples whose residual material in the paraffin block(s) is insufficient for neoplasm representation in the procedures in this study~* Cancer samples that have received previous chemotherapy treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast Cancer Participants (Type: None): Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Penicillin Allergy Testing in STD Clinics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior history of PCN allergy~Exclusion Criteria:~* No immunodeficiency or contraindication to skin testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Skin Testing Arm (Type: ACTIVE_COMPARATOR): These subjects with reported PCN allergy and reported low risk responses will receive skin testing followed by oral challenge
- Direct Oral Challenge (Type: ACTIVE_COMPARATOR): These subjects with reported PCN allergy and low risk responses will bypass skin testing and have direct oral challenge with amoxicillin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Understanding Different Parameters in Locomotor Training (a Type of Walking Training) for Person After a Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adults at least 18 years old;~* able to provide informed consent;~* able to follow three-step motor command;~* have a single unilateral stroke;~* medically stable (i.e. asymptomatic for bladder infection, decubiti, osteoporosis, cardiopulmonary disease, pain, or other significant medical complications that would prohibit or interfere with walking;~* able to stand with assistance and/or ambulate 15 meters with or without an assistive device or brace and no greater than standby physical assistance.~Exclusion Criteria:~* weight \> 300 pounds due to limitations in body weight support systems;~* body size which is incompatible with harnesses;~* pregnancy;~* presence of significant musculoskeletal problems that limit hip and knee extension or ankle plantarflexion to neutral;~* self selected walking speed below 0.3 m/s; and~* history of congestive cardiac failure, unstable angina, or peripheral vascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Stroke Survivors (Type: None): Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Recurrence in Depression With Drugs and CT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or chronic major depressive disorder~Exclusion Criteria:~* Current diagnosis of psychotic affective disorder~* History of nonaffective psychotic disorder~* Substance dependence last three months requiring detox~* Schizotypal, antisocial, or borderline personality disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive therapy plus medications (Type: EXPERIMENTAL): Participants will receive antidepressant medication plus cognitive therapy
- Medications alone (Type: EXPERIMENTAL): Participants will receive maintenance of antidepressant medication alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis~* attending a specialist liver clinic at Ninewells Hospital, Dundee~Exclusion Criteria:~* unstable cardiovascular disease~* uncontrolled arrhythmias~* structural cardiac abnormalities~* uncontrolled diabetes~* other uncontrolled metabolic abnormalities~* severe orthopaedic condition that would prohibit exercise~* severe pulmonary condition that would prohibit exercise~* any other poorly controlled medical condition.~* resting systolic blood pressure above 160 mm Hg~* resting diastolic blood pressure above 90 mm Hg~* symptomatic postural drop in blood pressure greater than 20 mm Hg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- High-intensity Interval Training (HIT) (Type: EXPERIMENTAL): 6 week control period with no intervention then 6 weeks of twice weekly HIT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In local pretrial services program; English speaking~Exclusion Criteria:~* Psychosis, inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- brief therapy (Type: EXPERIMENTAL): motivational enhancement therapy for substance use
- Standard Care (Type: PLACEBO_COMPARATOR): standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel Biomarkers of Thrombotic Risk

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Myocardial infarction demonstrated by elevated markers of cardiac injury (troponin I (TNI) or creatine kinase (CK) MB fraction)~* the presence of coronary artery disease demonstrated by cardiac catheterization or perfusion imaging~Exclusion Criteria:~* Treatment with long term anticoagulants~* active infection~* malignancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient, male and female 18 to 60 yrs old~* PTSD diagnostic according to DSM-IV criteria~* Patients who agree to receive diagnostic after SCID I application by a trained psychiatrist~* Sexually active female patients who agree to use contraceptive~* Patients who agree to sign the IRB approved informed consent~Exclusion Criteria:~* Patients who have schizophrenic disorder, delusional, psychotic depression, schizo-affective, bipolar and dependence to psychoactive substance disorders~* Patients who have clinical disorders not compensated, which require clinical treatment as priority~* Pregnancy~* Previous renal calculosis history~* Being under antidepressant, or other psychotropic medications~* BMI under 20.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Topiramate (Type: EXPERIMENTAL): patients receiving the active drug: topiramate
- Placebo Control group (Type: PLACEBO_COMPARATOR): patients received pills content placebo, that were identical to the pills content active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete